GlassScriptPhysician profile
Connie Mengyan Wang
NPI 1003250457
$49,370.87
in general payments reported to CMS, 2019-2025
38 companies · $3,650 in 2025
The $3,650 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,986 · 2020: $1,756 · 2021: $13K · 2022: $21K · 2023: $2,838 · 2024: $3,571 · 2025: $3,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,765 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,764.77 |
| Education | $294.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28,973.33 | 2019-2022 | |
| Abbvie INC. | $2,260.61 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Galderma Laboratories, L.P. | $1,920.38 | 2019-2025 | Dysport, Aklief, Nemluvio |
| Regeneron Healthcare Solutions, INC. | $1,741.97 | 2019-2025 | Dupixent |
| Revance Therapeutics, INC. | $1,688.52 | 2024-2025 | Daxxify, Daxi |
| Novartis Pharmaceuticals Corporation | $1,470.56 | 2019-2025 | |
| Janssen Biotech, INC. | $1,408.52 | 2019-2025 | Tremfya, Remicade, Simponi |
| Mayne Pharma Commercial LLC | $1,160.02 | 2019-2025 | |
| Genzyme Corporation | $1,038.15 | 2019-2025 | |
| Lilly USA, LLC | $972.05 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $769.32 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $706.77 | 2023-2025 | Zoryve |
| Pfizer INC. | $640.01 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $580.01 | 2020-2025 | Absorica Ld, Winlevi, Ilumya |
| Incyte Corporation | $448.44 | 2021-2025 | Opzelura |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connie Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.